Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
InspireMD ( (NSPR) ) just unveiled an announcement.
InspireMD, Inc. has enrolled its first patient in the CGUARDIANS II clinical trial, a significant milestone for its CGuard Prime Carotid Stent System used in Transcarotid Artery Revascularization. This study aims to expand the application of this innovative stenting platform, offering improved protection against strokes with a potential FDA approval on the horizon, addressing a growing U.S. market of 30,000 procedures annually.
For a thorough assessment of NSPR stock, go to TipRanks’ Stock Analysis page.
